Scientific DirectorJanssen Research & Development, LLCRaritan, New Jersey, United States
OC 66.3 - A model-based meta-analysis leveraging total knee replacement (TKR) data for selection of the milvexian dose for a phase 3 study in participants with atrial fibrillation.
Tuesday, June 25, 202415:15 – 15:30 ICT